TABLE 2.
Univariate and multivariate analysis for PFS.
| Variable | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | |
| Gender | 1.698 (0.544–5.298) | .362 | ||
| Age (<60; ≥60), years | 0.832 (0.263–2.636) | .755 | ||
| No. of extranodal involvement (0–1; ≥2) | 6.519 (1.747–24.325) | .005 | 5.6 (0.807–39.179) | .081 |
| LDH (normal; rise) | 1.922 (0.561–6.587) | .298 | ||
| Ann Arbor stage (II; III–IV) | 10.734 (1.385–83.192) | .023 | 2.66 (0.21–33.73) | .450 |
| IPI risk group (0–2; 3–5) | 2.88 (0.864–9.6) | .085 | ||
| Cell of origin (Hans) non‐GCB; GCB | 0.696 (0.09–5.4) | .729 | ||
| BCL‐6 rearrangement | 0.289 (0.084–0.997) | .049 | 0.247 (0.068–0.9) | .034 |
| TP53 mutation | 0.24 (0.03–1.97) | .18 | ||
| ECOG | 1.308 (0.541–3.163) | .551 | ||
Abbreviations: CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; GCB, germinal center B‐cell type; HR, hazard ratio; IPI, International Prognostic Index; LDH, lactate dehydrogenase; non‐GCB, nongerminal center B‐cell type; PFS, progression‐free survival.